Oncology

Study examines the effect of a low-calorie, plant-based diet combined with vitamin C in helping to kill cancer cells.

Cancer care providers have increasingly been using biosimilars on a case-by-case basis with patients.

The clinical trial of teclistamab sought to identify a recommended phase 2 dose for patients with RRMM, with multiple IV doses and priming doses explored.

A recent study evaluated the efficacy of venetoclax monotherapy in participants with relapsed or refractory chronic lymphocytic leukemia.

With the groundbreaking advancements in specialty pharmacy, it is important to recognize the uniqueness of these medications and their respective patient populations.

The American Cancer Society is renewing efforts to increase HPV immunization as COVID-19 threatens to slow cancer prevention progress.

In the United States, these findings would translate to more than 269,000 prevented breast cancer cases and nearly 44,000 prevented cases of ovarian cancer.

As the most accessible member of the health care team, the pharmacist can provide patients with cancer with the information and support necessary to get through what might be the most challenging time of their lives.

The approval represents the first for a second-line treatment for adult patients who progressed during or after first-line therapy.

A fully human monoclonal antibody, cemiplimab targets the immune checkpoint receptor PD-1 on T cells, blocking cancer cells from using the PD-1 pathway to suppress T-cell activation.

Officials with the FDA have approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

Isatuximab-ifrc is the third monoclonal antibody approved for the treatment of R/R MM.

The rarity of disease states coupled with novel medication mechanisms and high costs lead to complexities in accessing treatment and optimizing outcomes.

These study results were announced by Eisai and Merck during the 2020 American Society of Clinical Oncology Virtual Scientific Program, May 29-31.

As clinicians, we must first understand the unique challenges that a patient is facing and then tailor our support to address their specific needs.

Pharmacists can deliver value-based oncology services as an integral part of the health care team to improve patient outcomes.

Sarcomas account for about 1% of all adult cancers and 15% of all pediatric cancers.

Many pharmacies may be missing significant, profitable opportunities...via generic pharmaceuticals.

The investigators found that patients with preexisting neutropenia could be managed on venetoclax, although use of G-CSF would likely also be required in conjunction with the treatment.

Both premenopausal and postmenopausal breast cancer rates are rising globally.

Although the treatment of cancer is facing many challenges, the pandemic is also creating massive amounts of new data with which to educate patients, conduct new research, and make more informed clinical decisions.

This Pharmacy Times Webcast provides an overview of how the COVID-19 pandemic has impacted the treatment and management of patients with cancer.

Following initial breast cancer diagnosis by mammography, MRI, or ultrasound, treatment is largely based upon the histologic subtype and staging of the tumor(s).

Data aggregation partners can provide value in their ability to pull clinical information from both the HSSP and electronic health records.

Meaningful breakthrough therapies are receiving accelerated approval based on evidence of impact on a surrogate end point rather than evidence of impact on the actual clinical benefit for which the drug is intended.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is indicated for adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment.

Earlier results of the FAST trial, which was launched in 2004, found that reducing the number of radiotherapy fractions to 5 was feasible and safe in the short term.

Patients with cancer diagnosed more than 24 months ago are at an increased risk of severe COVID-19.